Literature DB >> 23396975

Lysophosphatidic acid triggers mast cell-driven atherosclerotic plaque destabilization by increasing vascular inflammation.

Martine Bot1, Saskia C A de Jager, Luke MacAleese, H Maxime Lagraauw, Theo J C van Berkel, Paul H A Quax, Johan Kuiper, Ron M A Heeren, Erik A L Biessen, Ilze Bot.   

Abstract

Lysophosphatidic acid (LPA), a bioactive lysophospholipid, accumulates in the atherosclerotic plaque. It has the capacity to activate mast cells, which potentially exacerbates plaque progression. In this study, we thus aimed to investigate whether LPA contributes to plaque destabilization by modulating mast cell function. We here show by an imaging mass spectrometry approach that several LPA species are present in atherosclerotic plaques. Subsequently, we demonstrate that LPA is a potent mast cell activator which, unlike other triggers, favors release of tryptase. Local perivascular administration of LPA to an atherosclerotic carotid artery segment increases the activation status of perivascular mast cells and promotes intraplaque hemorrhage and macrophage recruitment without impacting plaque cell apoptosis. The mast cell stabilizer cromolyn could prevent intraplaque hemorrhage elicited by LPA-mediated mast cell activation. Finally, the involvement of mast cells in these events was further emphasized by the lack of effect of perivascular LPA administration in mast cell deficient animals. We demonstrate that increased accumulation of LPA in plaques induces perivascular mast cell activation and in this way contributes to plaque destabilization in vivo. This study points to local LPA availability as an important factor in atherosclerotic plaque stability.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23396975      PMCID: PMC3622323          DOI: 10.1194/jlr.M032862

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  39 in total

1.  Mast cell activation by lipoproteins.

Authors:  Jim Kelley; Gregory Hemontolor; Walid Younis; Chuanfu Li; Guha Krishnaswamy; David S Chi
Journal:  Methods Mol Biol       Date:  2006

2.  Gold-enhanced biomolecular surface imaging of cells and tissue by SIMS and MALDI mass spectrometry.

Authors:  A F Maarten Altelaar; Ivo Klinkert; Kees Jalink; Robert P J de Lange; Roger A H Adan; Ron M A Heeren; Sander R Piersma
Journal:  Anal Chem       Date:  2006-02-01       Impact factor: 6.986

3.  Mast cell tryptase deficiency attenuates mouse abdominal aortic aneurysm formation.

Authors:  Jie Zhang; Jiusong Sun; Jes S Lindholt; Galina K Sukhova; Mark Sinnamon; Richard L Stevens; Roberto Adachi; Peter Libby; Robert W Thompson; Guo-Ping Shi
Journal:  Circ Res       Date:  2011-04-14       Impact factor: 17.367

4.  Mast cell chymase induces apoptosis of vascular smooth muscle cells.

Authors:  M Leskinen; Y Wang; D Leszczynski; K A Lindstedt; P T Kovanen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-04       Impact factor: 8.311

5.  Lysophosphatidic acid mediates the rapid activation of platelets and endothelial cells by mildly oxidized low density lipoprotein and accumulates in human atherosclerotic lesions.

Authors:  W Siess; K J Zangl; M Essler; M Bauer; R Brandl; C Corrinth; R Bittman; G Tigyi; M Aepfelbacher
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-08       Impact factor: 11.205

6.  Mast cells induce vascular smooth muscle cell apoptosis via a toll-like receptor 4 activation pathway.

Authors:  Wijnand K den Dekker; Dennie Tempel; Ilze Bot; Erik A Biessen; Leo A Joosten; Mihai G Netea; Jos W M van der Meer; Caroline Cheng; Henricus J Duckers
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-05-31       Impact factor: 8.311

7.  Receptors for the anaphylatoxins C3a and C5a are expressed in human atherosclerotic coronary plaques.

Authors:  Riina Oksjoki; Petri Laine; Satu Helske; Pirjo Vehmaan-Kreula; Mikko I Mäyränpää; Philippe Gasque; Petri T Kovanen; Markku O Pentikäinen
Journal:  Atherosclerosis       Date:  2007-01-17       Impact factor: 5.162

Review 8.  Macrophage death and defective inflammation resolution in atherosclerosis.

Authors:  Ira Tabas
Journal:  Nat Rev Immunol       Date:  2009-12-04       Impact factor: 53.106

9.  Lysophosphatidic acid accelerates the development of human mast cells.

Authors:  Savita Bagga; Kursteen S Price; Debby A Lin; Daniel S Friend; K Frank Austen; Joshua A Boyce
Journal:  Blood       Date:  2004-08-19       Impact factor: 22.113

10.  Association between myocardial infarction and the mast cells in the adventitia of the infarct-related coronary artery.

Authors:  P Laine; M Kaartinen; A Penttilä; P Panula; T Paavonen; P T Kovanen
Journal:  Circulation       Date:  1999-01-26       Impact factor: 29.690

View more
  26 in total

Review 1.  Lysophospholipids in coronary artery and chronic ischemic heart disease.

Authors:  Ahmed Abdel-Latif; Paula M Heron; Andrew J Morris; Susan S Smyth
Journal:  Curr Opin Lipidol       Date:  2015-10       Impact factor: 4.776

2.  Source and role of intestinally derived lysophosphatidic acid in dyslipidemia and atherosclerosis.

Authors:  Mohamad Navab; Arnab Chattopadhyay; Greg Hough; David Meriwether; Spencer I Fogelman; Alan C Wagner; Victor Grijalva; Feng Su; G M Anantharamaiah; Lin H Hwang; Kym F Faull; Srinivasa T Reddy; Alan M Fogelman
Journal:  J Lipid Res       Date:  2015-02-02       Impact factor: 5.922

3.  CD14 is a key mediator of both lysophosphatidic acid and lipopolysaccharide induction of foam cell formation.

Authors:  Dong An; Feng Hao; Fuqiang Zhang; Wei Kong; Jerold Chun; Xuemin Xu; Mei-Zhen Cui
Journal:  J Biol Chem       Date:  2017-07-13       Impact factor: 5.157

4.  Lysophosphatidic acid and cardiovascular disease: seeing is believing.

Authors:  Andrew J Morris; Susan S Smyth
Journal:  J Lipid Res       Date:  2013-03-18       Impact factor: 5.922

Review 5.  The roles of autotaxin/lysophosphatidic acid in immune regulation and asthma.

Authors:  Seung-Jae Kim; Hyung-Geun Moon; Gye Young Park
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2020-01-29       Impact factor: 4.698

Review 6.  The autotaxin-LPA axis emerges as a novel regulator of lymphocyte homing and inflammation.

Authors:  Sara Knowlden; Steve N Georas
Journal:  J Immunol       Date:  2014-02-01       Impact factor: 5.422

7.  Effects of diet and hyperlipidemia on levels and distribution of circulating lysophosphatidic acid.

Authors:  Maria P Kraemer; Guogen Mao; Courtney Hammill; Baoxiang Yan; Yu Li; Fredrick Onono; Susan S Smyth; Andrew J Morris
Journal:  J Lipid Res       Date:  2019-09-04       Impact factor: 5.922

8.  Lysophosphatidic acid acts on LPA1 receptor to increase H2 O2 during flow-induced dilation in human adipose arterioles.

Authors:  Dawid S Chabowski; Andrew O Kadlec; Karima Ait-Aissa; Joseph C Hockenberry; Paul J Pearson; Andreas M Beyer; David D Gutterman
Journal:  Br J Pharmacol       Date:  2018-10-11       Impact factor: 8.739

Review 9.  Mast cells in human and experimental cardiometabolic diseases.

Authors:  Guo-Ping Shi; Ilze Bot; Petri T Kovanen
Journal:  Nat Rev Cardiol       Date:  2015-08-11       Impact factor: 32.419

Review 10.  Mast cells as effectors in atherosclerosis.

Authors:  Ilze Bot; Guo-Ping Shi; Petri T Kovanen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-08-07       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.